Safety and efficacy of prophylaxis for Pneumocystis jirovecii pneumonia involving trimethoprim-sulfamethoxazole dose reduction in kidney transplantation

Safety and efficacy of prophylaxis for Pneumocystis jirovecii pneumonia involving trimethoprim-sulfamethoxazole dose reduction in kidney transplantation

Abstract Background Trimethoprim-sulfamethoxazole (TMP-SMX) is the drug of choice for anti-Pneumocystis jirovecii pneumonia (PcP) prophylaxis in kidney transplant recipients (KTR). Post-transplant management balances preventing PcP with managing TMP-SMX-related adverse effects. TMP-SMX dose reductio...

Full description

Bibliographic Details
Main Authors: G. V. Ramesh Prasad, Jill Beckley, Mohit Mathur, Madhushankar Gunasekaran, Michelle M. Nash, Lindita Rapi, Michael Huang, Jeffrey S. Zaltzman
Format: Article
Language:English
Published: BMC 2019-04-01
Series:BMC Infectious Diseases
Subjects:
Adverse effects
Hyperkalemia
Leukopenia
Online Access:http://link.springer.com/article/10.1186/s12879-019-3944-0

Internet

http://link.springer.com/article/10.1186/s12879-019-3944-0

Similar Items